NEW YORK (GenomeWeb News) – Piper Jaffray today downgraded shares of Sequenom to Neutral, saying that its fight to stay ahead of competitors in the non-invasive fetal chromosome abnormalities testing space may result in greater costs to the company, while its ability to get reimbursement remains uncertain.

The investment bank previously had an Overweight rating on the San Diego-based firm. Piper Jaffray also lowered the price target on Sequenom's shares to $5 from $6.50.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

An Australian study of personalized medicine has run into problems as it recruits patients.

In Science this week: mtDNA analysis give glimpse into decline of Neanderthals in Europe, and more.

The University of Arizona's Raina Maier writes that an understanding of the Earth's microbiome is needed.

The proposed Canadian budget emphasizes partnerships with industry, Nature News reports.

Apr
29
Sponsored by
Covance

This online seminar will review case studies demonstrating the clinical utility of CTCs and cfDNA to define and characterize a variety of dynamic genomic changes throughout the course of cancer detection and treatment.